The non-Hodgkin’s lymphoma (NHL) therapy market is dominated by patient-share leader rituximab (Roche/Genentech/Chugai Seiyaku/Zenyaku Kogyo’s Rituxan/MabThera). Through 2022, rituximab will maintain its dominance in the face of competition from biosimilars, but novel emerging drug classes will contribute to growth of the overall market. Untapped clinical and commercial potential remains in the NHL market for therapies with improved efficacy and for agents to treat currently underserved NHL subpopulations.
Questions Answered in This Report:
Rituximab is widely used across all NHL drug-treated populations and garners significant sales; however, it faces an enormous threat from biosimilars and from new drugs such as obinutuzumab (Roche/Genentech/Chugai/Glycart). How will rituximab’s market share change over the ten-year forecast period as a result of competition from biosimilars and new drugs? How will Roche seek to minimize the impact of biosimilar rituximab on sales of branded Rituxan/MabThera?
Despite the entry of biosimilar rituximab, we forecast robust annual growth of the NHL therapy market through 2022. What factors will drive this growth? Will monoclonal antibodies continue to dominate the treatment of NHL? What new classes of agents will emerge over the forecast period, and what impact will they have on the overall NHL market?
Although combination chemoimmunotherapy regimens dominate medical practice and are clinically successful in many NHL populations, high unmet need remains. What are the unmet needs in discrete NHL populations? Which of these needs will be satisfied by current or emerging agents?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 22 country-specific interviews with thought leaders.
Epidemiology: Diagnosed incidence of follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma.
Population segments in market forecast: First-line follicular lymphoma, second-line follicular lymphoma, third-line follicular lymphoma; first-line diffuse large B-cell lymphoma, second-line diffuse large B-cell lymphoma, third-line diffuse large B-cell lymphoma; first-line mantle cell lymphoma, second-line mantle cell lymphoma, third-line mantle cell lymphoma; first-line chronic lymphocytic leukemia, second-line chronic lymphocytic leukemia, third-line chronic lymphocytic leukemia.
Emerging therapies: Phase II: 29 drugs; Phase III: 6 drugs; preregistration: 3 drugs.
Alternative market scenario: Launch of Roche/Genentech/AbbVie’s ABT-199 for the treatment of relapsed/refractory chronic lymphocytic leukemia.